A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)

Kinoshita, T.; Shinoda, Masahiro; Nishizaki, Yasuhiro; Shiraki, Katsuya; Hirai, Yuji; Kichikawa, Yoshiko; Tsushima, Kenji; Shinkai, Masaharu; Komura, Naoyuki; Yoshida, Kazuo; Kido, Yasutoshi; Kakeya, Hiroshi; Uemura, Naoto; Kadota, Jun‐ichi

doi:10.1186/s12916-022-02518-7

Public

A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)

Published in BMC Medicine • Sep 26, 2022

Authors:

T. Kinoshita

Masahiro Shinoda

Yasuhiro Nishizaki

Abstract

BACKGROUND: In vitro drug screening studies have indicated that camostat mesilate (FOY-305) may prevent SARS-CoV-2 infection into human airway epithelial cells. This study was conducted to investigate whether camostat mesilate is an effective treatment for SARS-CoV-2 infection (COVID-19). METHODS: T...

Subject

Medicine

Placebo

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!